Rhythm Pharmaceuticals’ push to move obesity patients from jabs to tabs has stayed on beat. A phase 2 trial of the biotech’s next-generation oral candidate hit its primary endpoint, sending the stock ...
Bivamelagon showed significant BMI reductions in hypothalamic obesity patients, prompting Rhythm Pharmaceuticals to seek FDA guidance for Phase 3 trials. Rhythm Pharmaceuticals, Inc. announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results